Holen Sie sich die Stockscreener-App
10.34
1.27%
0.13
Handel nachbörslich:
10.34
Schlusskurs vom Vortag:
$10.21
Offen:
$10.31
24-Stunden-Volumen:
547.41K
Relative Volume:
0.67
Marktkapitalisierung:
$365.14M
Einnahmen:
$2.07M
Nettoeinkommen (Verlust:
$-47.68M
KGV:
-3.6667
EPS:
-2.82
Netto-Cashflow:
$-31.31M
1W Leistung:
+3.92%
1M Leistung:
+4.34%
6M Leistung:
-16.68%
1J Leistung:
-14.26%
1-Tages-Spanne:
$10.03
$10.56
1-Wochen-Bereich:
$9.99
$10.86
52-Wochen-Spanne:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Firmenname
Delcath Systems Inc
Sektor
Branche
Telefon
(518) 743-8892
Adresse
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Vergleichen Sie DCTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
10.34 | 360.55M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Craig Hallum | Buy |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2022-07-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-01-05 | Eingeleitet | BTIG Research | Buy |
| 2020-06-01 | Eingeleitet | Laidlaw | Buy |
Alle ansehen
Delcath Systems Inc Aktie (DCTH) Neueste Nachrichten
DCTH: HC Wainwright Reiterates Buy Rating with $30 Price Target - GuruFocus
HC Wainwright Reaffirms Buy Rating for Delcath Systems (NASDAQ:DCTH) - MarketBeat
Delcath Systems expects FY revenue of $85.2 million - MSN
Delcath reports $85.2 million in 2025 revenue, strong cash position By Investing.com - Investing.com Canada
Delcath Systems (DCTH) Exceeds Revenue Expectations in Q4 and Fu - GuruFocus
Delcath Systems announces preliminary fourth quarter and full year 2025 financial results - MarketScreener
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The AI Journal
ETF Watch: Will Delcath Systems Inc. stock remain a Wall Street favoriteTrade Ideas & Reliable Price Breakout Signals - ulpravda.ru
Will Delcath Systems Inc. stock remain a Wall Street favoriteMarket Volume Summary & Daily Technical Forecast Reports - ulpravda.ru
Shorts Report: Will Delcath Systems Inc stock remain a Wall Street favorite2025 Earnings Impact & Daily Growth Stock Investment Tips - moha.gov.vn
A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT - Sahm
Under the Radar: 3 Microcap Growers Passing a Tough Test - Benzinga
Will Delcath Systems Inc. stock sustain high P E ratios2026 world cup usa national team round of 16 key players high defensive line match prediction expert opinion - ulpravda.ru
Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative - Sahm
(DCTH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors? - Yahoo Finance
Are options traders betting on a big move in Delcath Systems stock? - MSN
Delcath Systems Inc Stock Analysis and ForecastLong-Term Growth Stocks & Fast Growing Investment Plans - earlytimes.in
Hepzato Kit Safe, Effective in Metastatic, Unresectable Uveal Melanoma - Cure Today
Are Options Traders Betting on a Big Move in Delcath Systems Stock? - Yahoo Finance
Delcath Systems publishes results from subgroup analyses of FOCUS study - Yahoo Finance
Delcath’s HEPZATO shows consistent efficacy across patient subgroups By Investing.com - Investing.com Nigeria
Delcath Systems (DCTH) Reveals Key Findings from FOCUS Study Sub - GuruFocus
Delcath’s HEPZATO shows consistent efficacy across patient subgroups - Investing.com
Which metastatic uveal melanoma patients gain most from a liver-directed drug? - Stock Titan
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma - Yahoo Finance
Simplify Asset Management Inc. Increases Stock Position in Delcath Systems, Inc. $DCTH - MarketBeat
Glenmark Pharmaceuticals Limited (532296) Gets Regulatory ApprovalFibonacci Extensions & Build Wealth With Strategy - bollywoodhelpline.com
Book value per share of Delcath Systems, Inc. – MUN:DV3R - TradingView — Track All Markets
Bearish Setup: Is Delcath Systems Inc stock a smart buy before Fed meetingTrade Entry Summary & Advanced Technical Signal Analysis - moha.gov.vn
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Delcath Systems, Inc. (NASDAQ:DCTH) is a favorite amongst institutional investors who own 51% - Yahoo Finance
Delcath Systems (STU:DV3R) EV-to-OCF : 19.88 (As of Dec. 21, 2025) - GuruFocus
Why Delcath Systems Inc. (DV3R) stock stays on buy lists2025 Biggest Moves & Entry Point Strategy Guides - bolumsonucanavari.com
Delcath Systems Earnings Notes - Trefis
Delcath Systems authorizes $25 million share repurchase program - MSN
Can Delcath Systems Inc. (DV3R) stock hold up in economic slowdownCEO Change & Risk Controlled Daily Trade Plans - Bölüm Sonu Canavarı
Do Options Traders Know Something About Delcath Systems Stock We Don't? - MSN
Will Delcath Systems Inc. (DV3R) stock sustain bullish trend into 2025Inflation Watch & Long-Term Safe Return Strategies - DonanımHaber
Is Delcath Systems Inc. stock a safe haven assetPortfolio Return Report & Reliable Intraday Trade Plans - Улправда
Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Here’s What Hit Delcath Systems (DCTH) in Q3 - Insider Monkey
How Delcath Systems Inc. (DCTH) Affects Rotational Strategy Timing - Stock Traders Daily
Vivo Capital LLC Decreases Stake in Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates - sharewise.com
How higher bond yields impact Delcath Systems Inc. (DV3R) stock2025 Key Highlights & High Conviction Investment Ideas - Newser
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH) and Champions Oncology (CSBR) - The Globe and Mail
How Delcath Systems Inc. (DV3R) stock reacts to Fed tighteningPortfolio Risk Summary & Daily Stock Trend Watchlist - Newser
Why Delcath Systems Inc. (DV3R) stock trades below fair valueQuarterly Trade Report & Daily Stock Trend Reports - Newser
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma - BioSpace
Finanzdaten der Delcath Systems Inc-Aktie (DCTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.31%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):